ロード中...
Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer
Angiogenesis has been implicated in ovarian cancer pathogenesis. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been incorporated in ovarian cancer treatment in combination with chemotherapy both in a frontline setting and in disease recurrence. However, re...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4199819/ https://ncbi.nlm.nih.gov/pubmed/25336975 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S65522 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|